TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
Rohit Loomba(University of California San Diego), George Kemble, Jeffrey D. Wayne(Northwestern University), Mary E. Rinella(University of Chicago), Katharine Grimmer, William McCulloch, Veeral Ajmera(University of California San Diego), Kathryn Jean Lucas(Lucas Research), Robert G. Perry, Rizwana Mohseni(Catalina Research Institute), Julio Gutiérrez(Scripps Institution of Oceanography), Vlad Ratziu(Inserm), Brent A. Neuschwander‐Tetri(Saint Louis University), Robert S. Rahimi(Baylor University), Stephen A. Harrison(Pinnacle Clinical Research), Vincent Wai‐Sun Wong(Chinese University of Hong Kong), Gregory J. Gores(Mayo Clinic in Arizona), James F. Trotter(Baylor Scott & White Health), Marie O’Farrell(BD Biosciences (United States))
Cited by 216
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.4k